Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases

Completed

• Conditions: Arthritis, Rheumatoid
• Interventions: Drug: Meloxicam

• Registration Number: NCT02184065
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Observational study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Primary Completion: 2007-04
• Status Verified: 2014-07
• Study First Submitted: 2014-07-03
• Study First Submitted QC: 2014-07-08
• Last Update Submitted: 2014-07-08
• Study First Posted: 2014-07-09
• Last Update Posted: 2014-07-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22639

Inclusion Criteria

• Age of 12 or older and rheumatologic disease

Exclusion Criteria

• Hypersensitivity to meloxicam
• Hypersensitivity to other Non-steroidal anti-inflammatory drugs (NSAIDS)
• History of asthma, angioedema or urticaria secondary to NSAIDS
• Pregnancy or lactation
• Recent or current history of peptic ulcer disease, severe renal failure and severe hepatic failure

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Meloxicam	Meloxicam	-

Primary Outcome Measures

Name	Time	Method
Medical global evaluation on a 4-point scale	30 and 90 days
Intensity of symptoms at rest evaluated with a 4-point scale	30 and 90 days
Intensity of symptoms during movement evaluated with a 4-point scale	30 and 90 days